Company news

Zhejiang Medicine Co., Ltd. Class A (SSE:600216) news

Zhejiang Medicine Co., Ltd. Class A news releases on 6ix. Latest, Sep 8, 2026: "Zhejiang Medicine Co., Ltd."Announcement on Convening the 2026 Semi-annual…

Zhejiang Medicine Co., Ltd. Class A (SSE:600216) news

Press releases & updates

"Zhejiang Medicine Co., Ltd."Announcement on Convening the 2026 Semi-annual Performance Briefing

"Zhejiang Medicine Co., Ltd."Announcement on Progress in Repurchasing Shares

"Zhejiang Medicine Co., Ltd."Announcement on Resolutions of the 14th Meeting of the 10th Board of Directors

"Zhejiang Medicine Co., Ltd."Announcement on Initial Repurchase of Shares through Call Auction

"Zhejiang Medicine Co., Ltd."Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase

"Zhejiang Medicine Co., Ltd."Announcement on Resolutions of the 13th Meeting of the 10th Board of Directors

"Zhejiang Medicine Co., Ltd."Announcement on Expiration of the Share Reduction Plan of a Shareholder Holding More Than 5% of the Company's Shares and No Share Reduction

"Zhejiang Medicine Co., Ltd."Announcement on Implementation of Dividend Distribution for 2025

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Progress in Cooperation in Investment with a Private Fund

Announcement on Cooperative Investment with Private Fund

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

Announcement on the Self-Inspection Report on the Trading of Stocks by Insiders of Inside Information Related to the Spin-off of Affiliated Subsidiaries

Announcement on Resolutions of the 12th Meeting of the 10th Board of Directors

Announcement on 2025 Annual Profit Distribution Plan

Announcement on Plan of Shareholding Reduction through Call Auction by Shareholder with Over 5% Shares

Announcement on Initiation of Phase II Clinical Trial of ARX305

Announcement on C-Round Capital Increase of Subsidiary Novocodex Biopharmaceuticals with the Introduction of Strategic Investors and Waiver of Preemptive Subscription Rights

Announcement on No Shareholding Reduction upon Expiration of Shareholding Reduction Plan by Shareholder with Over 5% Shares

Announcement on the Results of Grants for the 2025 Restricted Stock Incentive Plan

Announcement on Progress in Change of Share Nature and Progress in Share Granting under 2025 Restricted Stock Incentive Plan

Announcement on Granting Restricted Stocks to Incentive Objects of 2025 Restricted Stock Incentive Plan

Self-Inspection Report on the Trading of Company's Stock by Information Insiders in 2025 Restricted Stock Incentive Plan

Publicity Description and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on the List of Incentive Objects in the 2025 Restricted Stock Incentive Plan

Abstract of 2025 Restricted Stock Incentive Plan (Draft)

Announcement on Convening the 2025 Semi-annual Performance Briefing

2025 Semi-annual Report

Announcement on XC2309 Injection Obtaining Notice of Approval for Drug Clinical Trial

Announcement on Implementation Result of Shares Repurchase and Share Changes

Announcement on Progress in Repurchasing Shares

Announcement on Expected Increase in Semi-annual Performance for 2025

Announcement on Shares Repurchased Reaching 1% of the Company's Share Capital and Repurchase Progress

Announcement on Election Results of Employee Directors for the 10th Board of Directors

Announcement on Subsidiary Xinchang Pharmaceutical Factory Passing On-site Inspection by FDA of the United States

Announcement on Using Some Idle Self-owned Funds for Entrusted Wealth Management

Announcement on Initially Repurchasing the Company's Shares through Call Auction

Announcement on Convening the 2024 Annual Performance Briefing

Announcement on Resolution of the 5th Meeting of the 10th Board of Directors

Announcement on Obtaining Commitment Letter for Share Repurchase Loans from Financial Institutions

Announcement on Plan for Repurchasing Shares through Call Auction

Indicative Announcement on Proposal of Chairman to Repurchase Shares

Announcement on the Shareholding Reduction Plan for Shareholders Holding More than 5% of Shares through Call Auction

Announcement on Obtaining Drug Registration Certificate for Compound Sodium Acetate Ringer's Injection

Announcement on the Subsidiary Zhejiang Novus Pharmaceuticals Co., Ltd. Passing On-site Inspection by FDA

Announcement on Expected Increase in Annual Performance for 2024

Announcement on Completion of Industrial and Commercial Registration for Changes in Equity Structure of Controlling Shareholder and Change of Actual Controller

Announcement on "Corporate Value and Return Enhancement" Action Plan

Indicative Announcement on Changes in Equity Structure of Controlling Shareholder and Actual Controller

Report for Q3 2024